Product Information
PAROXETINE MESYLATE 7.5 MG CAP is a generic product labeled by Padagis US LLC, priced at $2.6223 per EA under NDC 00574027930. Its NADAC has been published 463 times since Nov 22, 2017.
FDA first approved this application on Jun 28, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the paroxetine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
7.5 mg/1
Manufacturer
Padagis US LLCNDC
00574027930
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PAROXETINE MESYLATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA204516FDA Approved
6/28/2013
TE Code
AB
On Market Since
10/3/2017
Pharmacological Classes
Price Statistics
The NADAC for PAROXETINE MESYLATE 7.5 MG CAP has been published 463 times since Nov 22, 2017, and over the history we have for it it has declined 40.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6223 per EA |
|---|---|
| All-time high | $4.5944 (May 11, 2022) |
| All-time low | $2.1647 (Aug 20, 2025) |
| 52-week high | $2.8717 |
| 52-week low | $2.3612 |
| Median price | $3.8123 |
| Average price | $3.6511 |
| Largest weekly change | +47.4% (Mar 20, 2024) |
| Weeks tracked | 463 |
| Tracking since | Nov 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paroxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PAROXETINE MESYLATE 7.5 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for PAROXETINE MESYLATE 7.5 MG CAP, manufactured by Padagis US LLC, is $2.6223 per EA (NDC 00574027930), effective Sep 30, 2026.
How has the price of PAROXETINE MESYLATE 7.5 MG CAP changed over time?
Over the history we have for it, the NADAC for PAROXETINE MESYLATE 7.5 MG CAP has declined 40.8%. It has been tracked across 463 weekly CMS publications since Nov 22, 2017.
What are the highest and lowest recorded NADAC prices for PAROXETINE MESYLATE 7.5 MG CAP?
Since Nov 22, 2017, the NADAC for PAROXETINE MESYLATE 7.5 MG CAP has ranged from a low of $2.1647 (Aug 20, 2025) to a high of $4.5944 (May 11, 2022), with a median of $3.8123 per EA.
Are there cheaper alternatives to PAROXETINE MESYLATE 7.5 MG CAP?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PAROXETINE MESYLATE 7.5 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures PAROXETINE MESYLATE 7.5 MG CAP?
PAROXETINE MESYLATE 7.5 MG CAP (NDC 00574027930) is labeled by Padagis US LLC, and CMS classifies it as a generic product.